Vitalis Therapeutics Inc. — VitaFlow is a fictional program. This page records the published data each quantitative parameter was calibrated against — trial sizes, durations, endpoints, probability of success and cost per participant — so that a reader with clinical or pharmaceutical experience can check the work rather than take it on trust.
17
Sources cited
2,480
Pivotal participants
7.0%
Overall PoS
$43,992
Cost per participant
Contents
1. Why This Document Exists
VitaFlow is a fictional program. Every number in this suite is invented in the sense that no such drug exists and no such trial was run.
But invented is not the same as arbitrary. A fictional program whose parameters are implausible teaches nothing and, worse, is actively misleading to a reader who does not know the field well enough to spot it. So each quantitative choice here — trial sizes, durations, endpoints, probability of success, cost per participant — was calibrated against published data from real development programs and published cost studies.
This document records what was used and for what, so a reader with clinical or pharmaceutical experience can check the work.
An honest note on how this suite was produced. The governance methodology — the gate
structure, the two-tier criteria model, the condition mechanics, the tranche discipline — is
drawn from stage-gate practice and does not depend on any of the sources below. The
pharmaceutical parameters do. An earlier draft of this suite carried a Phase 3 probability
of success of 25% and a pivotal program of 1,240 participants; both were wrong, and both were
corrected against the sources at §4 after being checked. The figures now shown are the
corrected ones. That correction is recorded here rather than quietly absorbed, because a document
about auditability that hides its own revision would be self-defeating.
2. Trial Program
| Phase | Study | Design | N | Duration | Primary measures |
|---|---|---|---|---|---|
| Phase 1 | VTX-401-101 | SAD/MAD, healthy volunteers | 64 | 12 weeks | Safety, tolerability, pharmacokinetics |
| Phase 2 | VTX-401-201 | Randomized, double-blind, placebo-controlled dose-ranging | 480 | 36 weeks | Dose selection; percent weight change; tolerability by dose |
| Phase 3 | VTX-401-301 | Pivotal 1 — randomized, double-blind, placebo-controlled | 1,360 | 68 weeks | Co-primary: percent weight change; proportion achieving ≥5% |
| Phase 3 | VTX-401-302 | Pivotal 2 — randomized, double-blind, placebo-controlled, with active comparator arm | 1,120 | 68 weeks | Co-primary as 301; comparator arm supports market access (D-08) |
| Phase 3 | VTX-401-303 | Cardiovascular outcomes sub-study, nested (CR-02) | 640 | 68 weeks | MACE adjudication; hazard ratio upper bound |
Pivotal program total: 2,480 participants across two trials, plus a nested cardiovascular sub-study of 640 added under CR-02.
Where these numbers come from
- 68-week pivotal duration is the established convention for obesity weight-management trials, used across the semaglutide STEP program.
- Pivotal scale is set against SURMOUNT-2, which randomized 2,539 participants across four arms. A 2,480-participant program across two pivotals is comparable.
- Co-primary endpoints — percent change in body weight, and the proportion of participants achieving at least a 5% reduction — follow the convention used in SURMOUNT-3 and consistent with agency expectations for the indication.
- Enrolment criteria of BMI ≥30, or ≥27 with at least one weight-related comorbidity, match those used in published pivotal programs in this class.
- Dose escalation over 20 weeks reflects real practice in the class, where escalation runs 16 to 20 weeks. The target product profile at Product Definition §3 records 16 weeks as the target and 20 as the conceded position.
3. Probability of Success
The program uses the following phase transition probabilities.
| Transition | This program | Published benchmark |
|---|---|---|
| Phase 1 → Phase 2 | 47% | 47% (Citeline, 2014–2023) |
| Phase 2 → Phase 3 | 30% | 28% (Citeline); 30.8–34.5% in other analyzes |
| Phase 3 → Approval | 50% | 55% Phase 3 success × 92% filing-to-approval ≈ 51% |
| Overall from Phase 1 | 7.0% | 6.7% likelihood of approval (Citeline) |
Why this matters more than it looks. These three numbers drive the risk-adjustment argument
in the Program Charter §2, which is the suite's central
piece of financial reasoning. At Gate 0 the correct risk-adjusted net present value is
$96,000,000 — the full compounded probability applied to the $1,362,000,000
unadjusted figure. At Gate 4, two of the three conditionals have already resolved, so the live
figure is the Phase 3 conditional alone: $681,000,000.
Get the Phase 3 conditional wrong and the entire argument reports the wrong number while appearing perfectly self-consistent. That is precisely what happened in the earlier draft.
Get the Phase 3 conditional wrong and the entire argument reports the wrong number while appearing perfectly self-consistent. That is precisely what happened in the earlier draft.
4. Sources
| Source | What it informs | Citation |
|---|---|---|
| Citeline / Norstella phase transition data, 2014–2023 | Probability of success at each phase transition. Phase 1 47%, Phase 2 28%, Phase 3 55%, filing to approval 92%; overall likelihood of approval from Phase 1 6.7%. The program uses 47% / 30% / 50%, the last combining Phase 3 success with filing-to-approval. | Norstella, “Why are clinical development success rates falling?” (2024) https://www.norstella.com/insight/why-are-clinical-development-success-rates-falling/ |
| Wong, Siah & Lo, Biostatistics (2019) | Cross-check on overall likelihood of approval and phase transition methodology. | Estimation of clinical trial success rates and related parameters https://academic.oup.com/biostatistics/article/20/2/273/4817524 |
| STEP program (semaglutide 2.4 mg) | Pivotal trial duration of 68 weeks; once-weekly subcutaneous administration; magnitude of weight reduction against which the target product profile is set. | Wilding et al., New England Journal of Medicine (2021) https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 |
| SURMOUNT-2 (tirzepatide) | Pivotal trial scale. 2,539 participants randomized across four arms — the benchmark for the 2,480-participant pivotal program here. | FDA CDER review, application 217806Orig1s000 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217806Orig1s000StatR.pdf |
| SURMOUNT-3 (tirzepatide) | Co-primary endpoint convention — percent weight change plus proportion achieving ≥5% reduction — and the BMI ≥30 or ≥27-with-comorbidity enrolment criteria used here. | Wadden et al., Nature Medicine (2023) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667099/ |
| Tirzepatide vs semaglutide, SURMOUNT-5 statistical analysis plan | Dose-escalation duration — 16 weeks for semaglutide, 20 weeks for tirzepatide — which sets the target and conceded positions in the TPP. | ClinicalTrials.gov NCT05822830 https://clinicaltrials.gov/study/NCT05822830 |
| Sertkaya et al., per-patient pivotal trial cost | Phase 3 cost per participant. Median $41,117 for FDA-approved new drugs; the program budgets approximately $44,000. | Reported cost benchmarks across therapeutic areas https://www.sofpromed.com/how-much-does-a-clinical-trial-cost |
| DiMasi et al., via BMC Health Services Research (2024) | Phase 3 out-of-pocket cost per investigational compound ($54M) and the $17,520–$61,907 per-patient range used to sanity-check the budget. | Inclusion of phase III clinical trial costs in health economic evaluations https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-024-11638-0 |
| Moore et al., BMJ (2018), via Applied Clinical Trials | Pivotal program cost. Median $48M per pivotal trial; $45M median where two trials are required — the structure used here. | New research challenging steep costs of clinical trials https://www.appliedclinicaltrialsonline.com/view/new-research-emerges-challenge-steep-costs-clinical-trials |
| Tufts CSDD site activation and enrolment benchmarks | Site non-activation rate (~11% globally, 13% North America; 89% of sites activate and begin enrolling) used to judge the program's site position. | Enrollment Performance: Weighing the Facts, Applied Clinical Trials https://www.appliedclinicaltrialsonline.com/view/enrollment-performance-weighing-facts |
| 21 CFR 312.32 — IND safety reporting | The expedited reporting obligations: 7 calendar days for an unexpected fatal or life-threatening suspected adverse reaction from initial receipt; 15 calendar days for a serious and unexpected suspected adverse reaction from the determination that it qualifies. Also the adverse event / serious / unexpected / suspected definitions. | Electronic Code of Federal Regulations, Title 21 §312.32 https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.32 |
| 21 CFR 312.52 — Transfer of obligations to a CRO | The written-transfer framework, and the provision that any obligation not covered by the written description is deemed NOT transferred. Also 312.52(b): a CRO assuming an obligation is subject to the same regulatory action as a sponsor. | Electronic Code of Federal Regulations, Title 21 §312.52 https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-D/section-312.52 |
| FDA guidance — Pediatric Study Plans (PREA) | The iPSP is due no later than 60 calendar days after the End-of-Phase-2 meeting; FDA has 90 days to respond and the sponsor a further 90, within a 210-day agreement window. Failure to include an agreed iPSP in an application subject to PREA may be grounds for a refuse-to-file action. | FDA, Guidance for Industry: Pediatric Study Plans https://www.fda.gov/media/86340/download |
| FDA guidance — Formal Meetings Between the FDA and Sponsors (PDUFA VII) | Meeting types and procedural goals: Type A 30 days, Type B 60 days, Type B (End-of-Phase) 70 days, Type C 75 days, Type D 50 days, INTERACT 75 days. Preliminary responses are issued before the meeting and the sponsor has 3 calendar days to confirm the meeting is still needed. Official minutes issued within 30 days. | FDA draft guidance, September 2023 https://www.fda.gov/media/172311/download |
| DIA / CDISC TMF Reference Model | The industry-standard taxonomy for the Trial Master File: 11 zones, 48 sections, 249 artifacts and 607 sub-artifacts, built on the essential documents of ICH E6 Section 8. Used here as the completeness check for this suite's clinical document coverage. | CDISC / DIA TMF Reference Model v3.x https://www.cdisc.org/standards/trial-master-file-reference-model |
| ICH E9 and E3 | E9 governs statistical principles and requires the Statistical Analysis Plan to be finalized before database lock and unblinding; E3 defines the structure and content of the Clinical Study Report. | ICH harmonised guidelines https://www.ich.org/page/efficacy-guidelines |
| Published screen-failure benchmarks | Screen-failure rates of 20–80% depending on eligibility criteria; roughly one in three Phase 3 trials misses its enrolment target. Sets the context for the program's 29% screen-failure rate. | Clinical trial enrolment metrics; Tufts CSDD recruitment and retention analyzes https://www.bekhealth.com/blog/clinical-trial-enrollment-metrics-2026/ |
5. Cost Calibration
| Parameter | This program | Published benchmark |
|---|---|---|
| Phase 3 cost per participant | $43,992 | Median $41,117 for FDA-approved new drugs; published range $17,520–$61,907 |
| Pivotal program cost | $109,100,000 | Median $45M where two pivotal trials are required (Moore et al.); $54M out-of-pocket Phase 3 per compound (DiMasi et al.) |
| Phase 2 cost | $38,000,000 | $7–20M typical; higher here because the program carries a wider dose span and 480 participants |
| Phase 1 cost | $8,500,000 | $4–5M typical; ~$133k per volunteer here against a ~$137k benchmark |
| Contingency | 12% of base | 10–15% is described as industry practice for late-phase programs |
Where this program is deliberately simplified. The $217,000,000 base program is
larger than published median pivotal-trial costs and far smaller than the capitalized
industry-average cost of bringing a drug to market, which runs to hundreds of millions or more
depending on the study and whether it includes the cost of failures.
The difference is definitional and worth stating plainly: this budget is the out-of-pocket cost of one program that succeeds. It excludes the cost of the failed programs a real portfolio carries, and it excludes the capitalized cost of money over a 8-year development window. Both are real costs to a real company. Neither belongs in a program budget, which is why a stage-gate budget and a published industry cost-per-approved-drug figure are not comparable numbers and should never be set beside each other without this note.
The difference is definitional and worth stating plainly: this budget is the out-of-pocket cost of one program that succeeds. It excludes the cost of the failed programs a real portfolio carries, and it excludes the capitalized cost of money over a 8-year development window. Both are real costs to a real company. Neither belongs in a program budget, which is why a stage-gate budget and a published industry cost-per-approved-drug figure are not comparable numbers and should never be set beside each other without this note.
6. What Is Not Calibrated
Several things in this suite are invented outright and rest on no source. They are listed so that a reader does not mistake them for research.
- The molecule. VTX-401 does not exist. Its claimed receptor engagement profile, and the therapeutic-window separation the whole differentiation thesis rests on, are invented.
- All clinical results. The Phase 2 figures quoted in the target product profile are plausible for the class but are not data. No trial was run.
- Every organization and individual. Vitalis Therapeutics, Meridian, Aldergate, Kestrel, Thorne & Vale and every named person are fictional.
- The agency interactions. The meeting dates, the positions taken, and the outcomes recorded are invented. Meeting types and their purposes are real.
- The commercial case. Market size, share, net price and the resulting revenue and NPV are illustrative. They are internally consistent and roughly plausible for the therapeutic area; they are not a market forecast.
The distinction the suite is built on. The methodology is real and is the thing
being demonstrated. The pharmacology is a setting chosen because it makes the methodology
concrete — and it has been calibrated well enough that a reader who works in the field
should not be distracted by implausibility. Where the two conflict, the methodology wins and this
page records the compromise.